Floatz logo

Erythropoietin

Female Reproductive System Neoplasm

Amgenprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Female Reproductive System Neoplasm cohort.

Asset / SponsorPhaseRating
Carboplatin
Wenjun Cheng
Phase 3BB
Peg-Rhg-Csf
Peking University
Phase 4BB
Adriamycin
Amgen
Phase 3BB
Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-
Sichuan Cancer Hospital and Research Institute
Phase 3BB
Pembrolizumab
Sheba Medical Center
Phase 2B

View all 29 →

Same molecule, other indications

Erythropoietin is also rated in:

anemiaDormant
BBB
Indicative · Phase 4
78 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative · Phase 4
65 / 100
View asset →
liver failureDormant
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →